Special Issue "Ocular Inflammation and Neuroimmunology"

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 222

Special Issue Editor

University of Melbourne, Parkville 3010, Australia
Interests: innate immunity; retinal degenerations; age-related macular degeneration (amd); science & technology; life sciences & biomedicine; ophthalmology; animals; macular degeneration; retina

Special Issue Information

Dear Colleagues,

Retinal inflammatory disease (or uveitis) is an eye condition that causes dysfunction of the retina and, in the most severe cases, substantial vision loss. It is most common in people between the ages of 20 and 60. And retinal degeneration is a retinopathy which consists in the deterioration of the retina caused by the progressive death of its cells. Neuroimmunology is a field combining neuroscience, the study of the nervous system, and immunology, the study of the immune system. Recent research has been exploring the role of innate immune signalling cascades in driving inflammation and leukocyte recruitment in retinal dystrophies such as age-related macular degeneration (AMD) and uncovering innovative therapeutics in order to suppress inflammation and improve patient outcomes.

This Special Issue focuses on inflammation in ocular diseases and neuroimmunology research. Submission of original articles, systematic reviews, short communications, and other types of article on related topics are welcome. Manuscripts will follow standard Journal peer-review practices, and those accepted for publication will appear in the special issue on Ocular Inflammation and Neuroimmunology. We look forward to receiving and welcome your contributions.

Dr. Matthew Rutar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Neuroimmune
  • Retinal inflammation
  • Retinal degeneration
  • Innate immune signaling cascades
  • Stem Cell
  • Macrophage
  • Chemokine
  • Receptor

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop